

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10I <small>100% seen=3,867</small> • I13V <small>100% seen=3,332</small> • E35D <small>100% seen=3,181</small> • M36I <small>100% seen=3,138</small> • R41K <small>100% seen=3,130</small> • L63P <small>100% seen=3,723</small> • H69K <small>100% seen=3,335</small> • L89M <small>100% seen=1,938</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
• L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None
NNRTI Mutations:	K103NS <small>91.42% seen=62</small> N: 42% seen=26
RT Other Mutations:	K11T <small>100% seen=2,352</small> • K20R <small>100% seen=2,383</small> • K22KR <small>91.71% seen=2,825</small> N: 71% seen=1,281 • V35T <small>100% seen=1,280</small> • T39R <small>100% seen=1,283</small> • K43Q <small>100% seen=2,379</small> • K49R <small>100% seen=1,304</small> • V60I <small>100% seen=212</small> • K122E <small>100% seen=629</small> • D123N <small>100% seen=629</small> • I142V <small>100% seen=1,111</small> • T165L <small>100% seen=1,311</small> • K173S <small>100% seen=1,299</small> • D177E <small>100% seen=2,291</small> • T200A <small>100% seen=1,817</small> • I202V <small>100% seen=1,825</small> • Q207A <small>100% seen=1,328</small> • V245Q <small>100% seen=2,388</small> • E248N <small>100% seen=1,135</small>

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments	
NNRTI	
• K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.	
• K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
K103NS	0	60	0	60	0